The Growth Hormone Axis: Overview
The growth hormone axis, also called the somatotropic axis, is the layered signaling system that governs how growth hormone (GH) is produced and released. Understanding the growth hormone axis is essential for interpreting the pharmacology of the many research peptides classified as GH secretagogues. This explainer walks through the hypothalamic-pituitary control loop, the two main signaling inputs, and the role of insulin-like growth factor 1 (IGF-1).
The material below is presented purely in research and receptor-biology terms. The peptides referenced are supplied for research use only and are not for human or animal consumption. No therapeutic, dosing, or efficacy claims are made or implied. GH secretagogues are studied in laboratory settings as tools for probing pituitary signaling, receptor selectivity, and feedback regulation. By clarifying how each class of secretagogue maps onto a specific node of the axis, we aim to give research professionals an accurate framework for comparing these study compounds and the receptor pathways they engage.
Recommended Products
Hypothalamus, Pituitary, GHRH, IGF-1
GH release is controlled by a hierarchy that begins in the hypothalamus and acts on the anterior pituitary. Two hypothalamic signals set the tempo, and a peripheral feedback hormone closes the loop:
- GHRH (growth hormone-releasing hormone) binds the GHRH receptor on pituitary somatotrophs to stimulate GH synthesis and release.
- Somatostatin is the inhibitory brake that suppresses GH release.
- Ghrelin acts at the growth hormone secretagogue receptor (GHS-R1a) to amplify GH release; synthetic ghrelin mimetics are termed GHRPs (growth hormone-releasing peptides).
- IGF-1 is produced largely in the liver in response to GH and provides negative feedback to the hypothalamus and pituitary.
Research secretagogues are grouped by which node of the axis they engage:
| Class | Receptor target | Example research compound |
|---|---|---|
| GHRH analog | GHRH receptor | Sermorelin |
| Long-acting GHRH analog | GHRH receptor | CJC-1295 (no DAC) |
| Stabilized GHRH analog | GHRH receptor | Tesamorelin |
| Ghrelin mimetic (GHRP) | GHS-R1a | Ipamorelin |
| IGF-1 analog | IGF-1 receptor | IGF-1 LR3 |
A recurring theme in the literature is the study of GHRH-analog and GHRP-class peptides in combination, because they act at two distinct receptors (GHRH-R and GHS-R1a) and are investigated for complementary signaling. IGF-1 LR3 sits downstream of the axis, engaging the IGF-1 receptor directly rather than the pituitary, making it a useful tool for isolating GH-independent IGF-1 signaling in models.
How Researchers Study GH Secretagogues
Researchers investigate the growth hormone axis using pituitary cell-culture models, GHRH-receptor and GHS-R1a binding and cAMP or calcium-signaling assays, and IGF-1 readouts in hepatocyte and other models. Comparative potency and receptor-selectivity panels distinguish GHRH analogs from ghrelin mimetics. Relevant catalog compounds include Sermorelin 10mg, CJC-1295 no DAC 10mg, Ipamorelin 10mg, Tesamorelin 10mg, and IGF-1 LR3 1mg. For a comparative overview of this class, see our pillar guide, growth hormone secretagogues compared.
Handling notes for research settings: these peptides are typically stored lyophilized, sealed, and cold; reconstituted with an appropriate sterile diluent for laboratory use; and refrigerated with minimized freeze-thaw cycling to protect peptide integrity. Aseptic technique and documented storage support reproducible results. All materials are for research use only and are not for human or animal consumption.